Formulation and specifications: Tablets: 100 mg, 200 mg
Indications: Sevotinib is used in adult patients with locally advanced or metastatic NSCLC with exon 14 jump mutations in mesenchymal-epithelial transforming factor (MET) who have disease progression after platinum-containing chemotherapy or who are intolerant to standard platinum-containing chemotherapy.
Key points for rational drug use:
1. A well-validated assay must detect the MET exon 14 jump mutation prior to drug administration. For pulmonary sarcomatoid carcinoma, more attention should be paid to detecting MET exon 14 jump mutations.
2. The recommended starting dose of sevotinib is 600 mg for patients weighing ≥50 kg and 400 mg orally once daily for patients weighing <50 kg.
3. Adjust the dose according to the safety and tolerability of the individual patient.
| SevotinibDaily oral dose | ||
| Starting dose | 600mg once daily (weight ≥ 50kg) |
400mg once daily (weight <50kg) |
| Dose level-1 (first dose reduction) | 400mg once daily | 300mg once daily |
| 300mg once daily | 200mg once daily | |
| 200mg once daily | – | |
.
4. The occurrence of hepatotoxicity, fever, edema, and hypersensitivity reactions need to be noted during drug administration. Adverse reactions with an incidence of ≥10% are nausea, edema, fatigue/weakness, vomiting, loss of appetite, hypoalbuminemia, anemia, fever, diarrhea, and elevated AST and ALT.
5. Concomitant use with strong inducers of CYP3A4 (e.g., phenytoin, rifampin, and carbamazepine) should be avoided. Combination with moderate inducers of CYP3A4 (e.g., bosentan, efavirenz, etravirine, and modafinil) should be avoided with caution or when possible. For St. John’s Wort and its extracts should be contraindicated for 3 weeks prior to the administration of this product. Metformin should be used with caution and monitored for possible risks due to increased metformin exposure.